Pomerantz probes Dr. Reddy's after semaglutide hit Q1 earnings
- Pomerantz LLP investigates Dr. Reddy's for potential securities fraud
- Q1 FY27 EPS fell to $0.06 due to ₹2.4 billion semaglutide provision
- Stock price dropped 9.4% to $11.38 following earnings announcement
*this image is generated using AI for illustrative purposes only.
Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy’s Laboratories Limited (NYSE: RDY) regarding potential securities fraud. The inquiry focuses on whether the company and its officers engaged in unlawful practices concerning recent financial disclosures.
The investigation stems from Dr. Reddy’s July 22, 2026 announcement of first quarter fiscal 2027 results. The company reported earnings per share of only $0.06, a figure attributed in part to a ₹2.4 billion provision related to out-of-specification semaglutide batches.
Impact on stock and margins
Following the earnings release, Dr. Reddy’s stock price fell $1.18 per share, or 9.4%, to close at $11.38 per share on July 22, 2026. CEO Erez Israeli stated that the quarter’s EBITDA margin was adversely impacted by semaglutide-related challenges. These challenges included lower sales, provisions for rejected batches, loss of production-linked incentives, and other associated costs.
What the numbers show
The disclosure highlights a direct correlation between product quality issues and immediate financial performance. The ₹2.4 billion provision for rejected batches directly reduced the reported EPS to $0.06, demonstrating how manufacturing non-conformances in high-value drugs like semaglutide can materially compress short-term profitability. Additionally, the loss of production-linked incentives suggests regulatory or compliance hurdles extended beyond simple batch rejection, affecting broader revenue streams.
Legal context
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, the firm has recovered numerous multimillion-dollar damages awards on behalf of class members. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The firm notes that prior results do not guarantee similar outcomes.
Will the loss of production-linked incentives trigger broader regulatory scrutiny or FDA inspections for Dr. Reddy’s other manufacturing facilities?
How might the semaglutide batch failures impact Dr. Reddy’s long-term partnerships with major GLP-1 drug developers and supply chain reliability?
What specific remediation timelines has management outlined to resolve the out-of-specification issues and restore investor confidence in Q2 fiscal 2027?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
